Woburn Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Woburn
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Woburn News
Aptima Celebrates 30 Years, Unveils Brand Refresh, and Announces New Board of Directors
Aptima, Inc., a technological innovator creating mission-ready, national security solutions, today announced the launch of a brand refresh in celebration of its 30th anniversary and the appointment of ...
Petition to fight ‘devastating’ closure of Rushmere Country Park bike jumps
The planned closure of Rushmere Country Park bike jumps near Leighton Buzzard has received a huge backlash from the mountain biking community.
Are university policies holding science back? Study shows how patenting boosts pure research
When UC Berkeley biochemist Jennifer Doudna first began studying how bacteria fight virus infections, she had no idea it would result in one of the most important scientific breakthroughs of the ...
NDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to ...